Targeted lung cancer drug shows promise in phase I/II clinical trial

Early trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain type of non-small cell lung cancer (NSCLC).

from Medical Xpress - latest medical and health news stories https://ift.tt/yD5lvFA